Zbigniew Nowecki
A5059490423- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cutaneous Melanoma Detection and Management
- Gastrointestinal Tumor Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Gastric Cancer Management and Outcomes
- Nonmelanoma Skin Cancer Studies
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Multiple and Secondary Primary Cancers
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Gastrointestinal disorders and treatments
- Radiopharmaceutical Chemistry and Applications
The Maria Sklodowska-Curie National Research Institute of Oncology
2015-2025
Institute of Cancer Research
2024
Ministry of Education
2024
Goethe University Frankfurt
2024
Harbin Medical University
2024
Cancer Research Institute
2024
University of Hong Kong
2024
Queen Mary University of London
2024
Seoul National University Hospital
2024
Cornell University
2024
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
1000 Background: Pembrolizumab (pembro) monotherapy showed promising antitumor activity and manageable safety in patients (pts) with metastatic TNBC KEYNOTE-012, -086 -119. KEYNOTE-355 (ClinicalTrials.gov, NCT02819518) compared pembro + chemotherapy (chemo) vs placebo (pbo) chemo for previously untreated locally recurrent inoperable or TNBC. Methods: Pts ≥6 mo DFI were randomized 2:1 to (nab-paclitaxel; paclitaxel; gemcitabine/carboplatin) pbo up 35 administrations of pembro/pbo until...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative advanced breast cancer. Whether this cancer extends early is unclear. Download PDF of the Research Summary. In international, open-label, randomized, phase 3 trial, we randomly assigned HR-positive, HER2-negative 1:1 ratio receive ribociclib (at dose 400 mg per day for weeks, followed by 1 week off, years) plus nonsteroidal...
Abstract Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) the Phase 1 SERENA-1 study1,2 with dose-dependent safety profile. The 2 randomized SERENA-2 study (NCT04214288) initially assessed three doses of C vs fulvestrant (F) post-menopausal women HER2˗ BC disease recurrence or progression after ≤1 endocrine therapy (ET) advanced setting. Methods evaluated...
BackgroundInavolisib is a highly potent and selective inhibitor of the alpha isoform p110 catalytic subunit phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes degradation mutated p110α. Inavolisib plus palbociclib–fulvestrant has shown synergistic activity in preclinical models promising antitumor early-phase trials.MethodsIn phase 3, double-blind, randomized trial, we compared first-line inavolisib (at an oral dose 9 mg once daily) (inavolisib group) with placebo...
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
1003 Background: INAVO120 (NCT04191499) showed significantly and meaningfully improved investigator-assessed progression-free survival (PFS; stratified hazard ratio 0.43) with Inavo+Palbo+Fulv v Pbo+Palbo+Fulv, manageable safety tolerability. To further characterize the substantial benefit/risk of Inavo triplet, we assessed additional clinically relevant efficacy endpoints, detailed data key adverse events (AEs) for (hyperglycemia [HG], diarrhea, rash, stomatitis), pt-reported outcomes...
In Brief Summary Background Data: The more intensive sentinel node (SN) pathologic workup, the higher SN-positivity rate. This is characterized by an increased detection of cases with minimal tumor burden (SUB-micrometastasis <0.1 mm), which represents different biology. Methods: slides positive SN from 3 major centers within European Organization Research and Treatment Cancer (EORTC) Melanoma Group were reviewed classified according to Rotterdam Classification Tumor Burden (<0.1 mm; 0.1–1...
Purpose Prognosis in patients with sentinel node (SN) –positive melanoma correlates several characteristics of the metastases SN such as size and site. These factors reflect biologic behavior may separate out who or not need additional locoregional and/or systemic therapy. Patients Methods Between 1993 2008, 1,080 (509 women 571 men) were diagnosed tumor burden nine European Organisation for Research Treatment Cancer (EORTC) group centers. In total, 1,009 (93%) underwent completion lymph...
The aim of the study was to analyze surgical possibilities unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment.We analyzed results surgery in 141 treated with for initially inoperable CD117(+). Median follow-up time 12 months (range: 3-26).Surgery performed as subsequent treatment 24 (Group I, 17%) resection residual disease after complete/partial response and lack further salvage therapy eight II, 6%), who progressed on successful therapy. In Group viable cells...
Purpose This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients human epidermal growth factor receptor 2-positive early breast cancer the neoadjuvant setting ( ClinicalTrials.gov identifier: NCT02149524). Patients and Methods were randomly assigned to receive SB3 or for eight cycles concurrently chemotherapy (four of docetaxel followed by four fluorouracil, epirubicin, cyclophosphamide) surgery, then 10 adjuvant TRZ. The primary objective was...
1023 Background: Chemotherapy with immune checkpoint inhibitors can improve outcomes vs chemotherapy alone in patients (pts) metastatic TNBC; however, many still have poor clinical outcomes. BEGONIA is an ongoing 2 part, multicenter, multiarm, open-label platform study evaluating safety and efficacy of D (anti–PD-L1)+P D±P combined novel therapies as first-line (1L) treatment for TNBC (NCT03742102). We report initial results from Part 1 Arm 1, D+P, 6, D+T-DXd, antibody-drug conjugate...
•Final safety and efficacy results from PERUSE with ∼6 years' median follow-up are consistent CLEOPATRA results.•Results provide reassurance that paclitaxel is a valid alternative to docetaxel first-line pertuzumab trastuzumab.•In exploratory analyses, presence of both visceral disease prior trastuzumab identified subgroup worse PFS. BackgroundThe phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination pertuzumab, as standard therapy for...
PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib-paclitaxel PI3K pathway-mutant HR+ unresectable locally advanced/metastatic cancer (aBC).Cohort of the randomized, double-blind, placebo-controlled, phase 3 trial enrolled patients with HER2-negative PIK3CA/AKT1/PTEN-altered measurable aBC who were considered inappropriate for endocrine-based therapy (demonstrated insensitivity to endocrine or visceral...
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients tumors that have progressed on endocrine therapy and/or are not eligible had limited treatment options beyond chemotherapy. Antibody-drug conjugates a novel and promising class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of TROP2-directed humanized IgG1 monoclonal antibody attached via serum-stable cleavable linker to topoisomerase I inhibitor payload. TROPION-Breast01...
Abstract Background: AKT pathway activation has been implicated in the development of endocrine therapy resistance hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer (ABC). In Phase II, placebo (PBO)-controlled FAKTION trial, addition pan-AKT inhibitor capivasertib to fulvestrant significantly improved progression-free survival (PFS) and overall postmenopausal women with aromatase (AI)-resistant HR+/HER2– ABC. The III, randomized,...